Athenex Revenue 2011-2026 | ATNX

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Athenex

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
103 M	95.4 M	144 M	101 M	89.1 M	38 M	20.6 M	13.9 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
144 M	13.9 M	75.7 M

Quarterly Revenue Athenex

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	33.5 M	-	29.7 M	-	31.4 M	21.9 M	41 M	21.8 M	35.5 M	40.2 M	46.9 M	34.4 M	19.4 M	22.2 M	25.3 M	21.3 M	18.4 M	11.6 M	37.8 M	14.9 M	14 M	4.6 M	4.58 M	5.11 M	5.62 M	5.19 M	4.63 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
46.9 M	4.58 M	22 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Drug manufacturers industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	28 K	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	19.6 M	-	10.11 %	$ 58.2 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.76 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	194 M	-	-	$ 754 M	USA
Catalent CTLT	4.38 B	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	8.55 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	317 M	-	-39.89 %	$ 27.7 M	USA
Alimera Sciences ALIM	80.8 M	-	-	$ 142 M	USA
Endo International plc ENDP	2.01 B	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	5.18 M	-	-	$ 36.6 M	USA
Avadel Pharmaceuticals plc AVDL	169 M	-	-	$ 2.06 B	France
Cumberland Pharmaceuticals CPIX	10.4 M	$ 3.06	-3.77 %	$ 43 M	USA
Cronos Group CRON	46.7 M	$ 2.66	3.31 %	$ 1.36 B	Canada
Calliditas Therapeutics AB (publ) CALT	874 K	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	191 M	-	2.45 %	$ 38.1 M	Canada
Sundial Growers SNDL	946 M	$ 1.51	4.51 %	$ 3.37 M	Canada
Jupiter Wellness JUPW	2.12 M	-	-	$ 33.6 M	USA
Bausch Health Companies BHC	8.76 B	$ 5.75	1.14 %	$ 2.1 B	Canada
Harrow Health HROW	272 M	$ 38.37	1.11 %	$ 1.41 B	USA
Aurora Cannabis ACB	175 M	$ 3.67	3.82 %	$ 86.3 M	Canada
Canopy Growth Corporation CGC	269 M	$ 1.14	4.58 %	$ 123 M	Canada
Tilray TLRY	627 M	$ 6.87	-0.65 %	$ 4.25 B	Canada
OrganiGram Holdings OGI	160 M	$ 1.48	3.5 %	$ 402 M	Canada
Lannett Company LCI	341 M	-	1.15 %	$ 7.11 M	USA
Veru VERU	16.9 M	$ 2.42	0.83 %	$ 326 M	USA
Viatris VTRS	15.4 B	$ 13.88	-0.25 %	$ 16.7 B	USA
Neoleukin Therapeutics NLTX	925 K	-	-	$ 193 M	Canada
Evolus EOLS	297 M	$ 4.45	0.23 %	$ 287 M	USA
Emergent BioSolutions EBS	1.05 B	$ 8.65	-0.12 %	$ 443 M	USA
Organogenesis Holdings ORGO	482 M	$ 2.53	0.8 %	$ 333 M	USA
Pacira BioSciences PCRX	542 M	$ 23.34	-1.73 %	$ 1.08 B	USA
PetIQ PETQ	1.1 B	-	1.64 %	$ 400 M	USA
ProPhase Labs PRPH	123 M	-	-	$ 5.07 M	USA
Relmada Therapeutics RLMD	5.13 K	$ 7.12	-0.97 %	$ 281 M	USA
Assertio Holdings ASRT	119 M	$ 18.03	0.06 %	$ 115 M	USA
cbdMD YCBD	19.5 M	$ 0.74	2.5 %	$ 3.19 M	USA
Radius Health RDUS	230 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	94.6 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	71 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	20.6 M	$ 1.08	5.88 %	$ 53.9 M	USA
PLx Pharma PLXP	8.21 M	-	-27.8 %	$ 2.56 M	USA
Sonoma Pharmaceuticals SNOA	14.3 M	$ 2.23	2.29 %	$ 2.77 M	USA
Zomedica Corp. ZOM	32 M	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	86 K	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	69.3 M	$ 0.89	-4.36 %	$ 32 M	USA
China Pharma Holdings CPHI	4.14 M	$ 0.65	5.21 %	$ 2.79 M	China
TherapeuticsMD TXMD	3.02 M	$ 2.04	-3.27 %	$ 23.6 M	USA